Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic diseases, has successfully raised tens of millions of renminbi in a Series B+ financing round. The funds will be allocated to the development and advancement of the company’s innovative pipelines and to support its robust antibody discovery platform. Investors in this round included Ruiying Asset, HMC Venture, and Wang Chunhua.
Company Background and Proprietary Technologies
Founded in 2017, Biosion has established a pipeline of innovative biologics through its internally derived proprietary technologies. These include the H³ antibody discovery platform, SynTracer high-throughput endocytosis platform, and Flexibody bifunctional platform. These technologies position Biosion at the forefront of antibody-based therapy development.
Lead Asset and Clinical Progress
Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in a Phase II study for severe asthma and Phase I for atopic dermatitis. The company’s pipeline also includes four additional drug candidates that are ready for patient enrollment in Phase I or II clinical trials in both China and the US.-Fineline Info & Tech
